Effects of Pulsed Electromagnetic Field Therapy on Sport Performance and Recovery

April 6, 2026 updated by: Kong Pui Wah, Nanyang Technological University

The goal of this clinical trial is to learn if pulsed electromagnetic field (PEMF) therapy works to improve sports performance and recovery in athletes. The main questions it aims to answer are:

  • Does PEMF therapy enhance participants' performance during exercise?
  • Does PEMF therapy enhance recovery in participants after exercise? Researchers will compare active PEMF therapy to sham PEMF therapy (using the same device for both, but without any electromagnetic fields) to see if active PEMF therapy is effective in improving sports performance and recovery.

Participants will:

  • Receive active pulsed electromagnetic field therapy or sham pulsed electromagnetic field therapy twice a week for 8 weeks.
  • Visit the laboratory at baseline, 8 weeks, and 12 weeks for sports performance and recovery assessments.

Study Overview

Detailed Description

This is a prospective, randomised, double-blind, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio investigating the effects of PEMF therapy on athletes. Participants will be recruited from the Physical Education and Sports Science Department at the National Institute of Education, Nanyang Technological University in Singapore. Researchers will monitor sports performance and recovery outcomes during baseline assessment and at the 8- and 12-week follow-ups after the start of Pulsed Electromagnetic Field (PEMF) therapy. The PEMF therapy will last for 8 weeks, with the final assessment scheduled at week 12. The outcomes measured at 8 weeks will reflect the short-term effects, while the final time point may indicate the carry-over effects of PEMF therapy on athletes.

The PEMF therapy will be administered using a commercial device (QuantumTX Pte). The delivery of PEMF to the leg will not produce heat or cause any sensation, which allows the participants to be blinded to the treatment. Participants in the control group will receive sham exposure with the same PEMF device. Each leg will undergo either active PEMF therapy or sham PEMF therapy for 10 minutes per session, with the treatment administered twice weekly for 8 weeks, resulting in a total of 16 sessions. The PEMF device will be activated by the Radiofrequency Identification (RFID) card, which will be coded to deliver either the active or sham PEMF treatment. The PEMF therapy procedure will be as follows: The participant will be seated in a 90° position on a chair, and the entire quadriceps muscle will be placed within the solenoids of the PEMF device. When active, the device delivered uniform 1.2 mT, 50 Hz PEMFs to each quadriceps muscle for 10 minutes.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Exercise at least twice a week in the past 3 months
  • Perform resistance training 1-3 times per week in the past 3 months.
  • Have competed in at least two matches / events in the past one year (e.g. heat and final are counted as two events).

Exclusion Criteria:

  • History of fracture or surgery over the past year.
  • History of musculoskeletal injury in the last 3 months that required more than 7 days of rest.
  • Currently experiencing any injury, discomfort and/or pain at the time of study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active PEMF Group
The active PEMF group will receive 8 weeks of active pulsed electromagnetic field therapy.
The experimental group will receive active Pulsed Electromagnetic Field (PEMF) therapy twice weekly for 8 weeks, for a total of 16 sessions. Participants will sit comfortably in a chair with their legs placed inside the solenoid of the PEMF device. The active PEMF settings are 1.2 milliTesla (mT) at 50 Hertz (Hz). Each PEMF session will last 20 minutes, with 10 minutes of active PEMF exposure per leg.
Sham Comparator: Sham PEMF Group
The sham PEMF group will receive 8 weeks of sham pulsed electromagnetic field therapy.
The control group will receive sham Pulsed Electromagnetic Field (PEMF) therapy twice weekly for 8 weeks, for a total of 16 sessions. Participants will sit comfortably in a chair with their legs placed inside the solenoid of the PEMF device. The sham PEMF settings are 0 milliTesla (mT) at 0 Hertz (Hz). Each PEMF session will last 20 minutes, with 10 minutes of sham PEMF exposure per leg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wingate anaerobic test rate of fatigue
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
The Wingate anaerobic test involves a 30-second all-out cycling effort performed while stationary. Participants pedal as fast as possible against a standardised resistance for 30 seconds. The percentage decline in power output is calculated from the peak power to the lowest power during the test. It measures how quickly an individual fatigues during intense anaerobic exercise and their capacity to sustain high power output.
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Blood lactate level
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Finger-prick blood sampling for lactate levels will be performed at 4 time points (baseline and 5, 15, and 30 min after the Wingate anaerobic test).
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wingate anaerobic test peak power
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
The Wingate anaerobic test involves a 30-second all-out cycling effort performed at a stationary position. Participants will pedal as fast as possible against a standardised resistance for 30 seconds. The highest power output achieved during the 30-second Wingate anaerobic test will be recorded as the peak power in Watts.
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Wingate anaerobic test mean power
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
The Wingate anaerobic test involves a 30-second all-out cycling effort performed at a stationary position. Participants will pedal as fast as possible against a standardised resistance for 30 seconds. The average power output achieved during the 30-second Wingate anaerobic test will be recorded as the mean power in Watts.
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Skeletal muscle mass
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Skeletal muscle mass in kilograms will be assessed using the InBody Body Composition Analyser while standing. Skeletal muscle mass specifically relates to muscles that can grow through training.
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Muscle stiffness
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Muscle stiffness of the vastus lateralis will be assessed using the MyotonPRO Digital Palpation Device at rest.
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Muscle oxygen saturation
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Muscle oxygen saturation of the vastus lateralis will be measured using Near-Infrared Spectroscopy (NIRS) before, during, and after the Wingate anaerobic test.
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Muscle activity
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Muscle activity of the vastus lateralis will be recorded using surface electromyography (EMG) during the Wingate anaerobic test.
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Strength
Time Frame: From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up
Strength will be measured using the isometric mid-thigh pull test. Participants will pull against a fixed metal chain while standing on the back extension dynamometer platform. The dynamometer will record the maximum force exerted.
From enrollment to the end of treatment at 8 weeks, and a 12-week follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Pui Wah KONG, PhD, Nanyang Technological University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 19, 2026

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

August 30, 2026

Study Registration Dates

First Submitted

November 16, 2025

First Submitted That Met QC Criteria

December 3, 2025

First Posted (Actual)

December 17, 2025

Study Record Updates

Last Update Posted (Actual)

April 8, 2026

Last Update Submitted That Met QC Criteria

April 6, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-2025-575

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will be shared upon reasonable requests.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Athlete

Clinical Trials on Active Pulsed Electromagnetic Field Therapy

Subscribe